People
The People Running Elixirr
Figures converted from GBP at historical FX rates — see data/company.json.fx_rates. Ratios, margins, multiples, share counts and percentages are unitless and unchanged.
Governance grade: B+. A founder-led consultancy with genuine skin in the game — CEO Stephen Newton owns 22.85% (~$113m at 744p / FX 1.3242) and the wider insider/director group ~28% — yet the governance scaffolding around the equity is thin. The 2025 Main Market admission has tightened disclosure, but the company explicitly opts out of three UK Corporate Governance Code provisions (no malus/clawback, sub-five-year RSA vesting, no director shareholding policy), and a March 2026 employee option reprice and a string of insider sales by the founder leave the alignment story imperfect rather than airtight.
1. The People Running This Company
Board Size
Executive Directors
Independent NEDs
CEO Stake (%)
The leadership has real consulting pedigree: Newton and Busby co-founded Elixirr in 2009 after senior partner roles at Accenture, and the Chairman is a credible heavyweight (BT, Salesforce). The new CFO Willott and new Deputy CEO Busby both took up enlarged roles on the same day — 1 January 2025 — which means the financial control function changed hands in the same year as the Main Market admission and a busy M&A programme. That is a thin succession bench: the entire executive layer is two co-founders plus a recent CFO promotion.
Bill Michael's KPMG exit is the only material reputational concern on the Board. He resigned as KPMG UK Chair in February 2021 after telling staff in a virtual meeting to "stop moaning" about lockdown and unconscious bias. The episode was widely reported and ended his executive career at the firm. He has been an unpaid adviser to Elixirr since December 2021, so the Board has had four years to assess fit before formalising the appointment in January 2026.
2. What They Get Paid
The pay mix is dominated by the cash annual bonus: Newton's $1.88m bonus was 4× his $469k base, taking total comp to $2.46m. On $26.5m of FY25 net income, the three executive directors drew roughly 22% of net profit in pay — high in absolute terms for a ~$487m-cap company but defensible because Newton's true wealth lever is his ~$113m equity stake, not the pay packet. The salary line itself is modest for a CEO running a $200m-revenue listed firm.
Three UKCG opt-outs the Remuneration Committee has confirmed it will not fix in FY26:
- No malus or clawback on bonuses or share awards (contrary to UKCG Provisions 37 & 38).
- RSAs vest over 3 years, not the 5+ years required by UKCG Provision 36.
- No formal director shareholding requirements or post-employment holding policy.
Performance targets are also withheld on commercial-sensitivity grounds, and no external remuneration consultant was used. None of these is fatal, but the cluster is a step below typical FTSE 250 standards as ELIX moves from AIM to the Main Market.
3. Are They Aligned?
Ownership & control
CEO Stephen Newton's 22.85% is the controlling individual stake. Including co-founder Busby (3.49%), other directors (~2.2%), and substantial individual shareholder Ian Ferguson (4.47%), insiders/related individuals control ~33% — enough to set strategic direction and to defend or block any control transaction. Institutions (Gresham House, Slater, Rathbone, Grandeur Peak, Otus, JPM, abrdn) own a similar share of the register, with no single hostile block.
Insider buying vs selling
The recent disclosed transactions are mixed but small in scale: NED Charlotte Stranner sold ~$501k worth (Jan 2024); Simon Retter (Rem-Co Chair) made small open-market purchases of ~$13k (Feb 2026) and ~$14k (Mar 2026). Founder Stephen Newton's headline holding has drifted lower over five years (~25–29% pre-IPO/AIM era → 22.85% as of March 2026), reflecting periodic founder placings. He has not been a buyer at any point since IPO. Stockholders should treat the founder as a slow seller.
Dilution and option repricing
On 20 March 2026, the Company repriced 4,396,040 employee options (issued Oct 2024 – Jan 2026) to an exercise price of $8.54. The repricing explicitly excluded Directors and Key Management Personnel — so there is no self-dealing — but it transfers value from existing shareholders to junior staff. With ~50m shares in issue, the repriced options represent ~8.8% of capital. Combined with FY25 RSA grants to Busby (476k subject to forfeiture) and Willott (136k), and 137k of new options to Newton at $10.50, dilution risk is meaningful and worth monitoring.
Capital allocation
Capital deployment in FY25 was disciplined-but-busy: the TRC Advisory acquisition; a 27% YoY increase in dividends to ~30¢ per share (~$11.3m total); ~$32.5m year-end net debt against ~$68.7m of facility headroom. Post year-end: Kvadrant acquisition (Jan 2026, ~$24m, partly stock-funded). Dividends grew faster than net income in FY25, but the Board funded that out of cash from operations rather than leverage. Operating cash flow comfortably covered the $11.3m payout. Acquisitions are the dominant use of cash, consistent with the partner-led roll-up model.
Skin-in-the-game scorecard
Skin-in-the-Game Score (out of 10)
| Factor | Reading |
|---|---|
| Founder/CEO stake | 22.85% (~$113m) — strong |
| Wider insider holding | ~28% — strong |
| NED shareholdings | Modest but real ($1.7m – $2.7m each) |
| Founder activity | Net seller over 5 years — drag |
| Formal shareholding policy | None — drag |
| Clawback/malus | None — drag |
| RSA vesting | 3 years (below UKCG 5y) — drag |
A 7/10. The economic alignment is genuine and large; the policy scaffolding around it is below FTSE 250 norms.
4. Board Quality
The Audit and Remuneration committees are chaired by genuine financial professionals (Stranner and Retter, both qualified CAs with AIM/small-cap experience). The Chair (Patterson) is the anchor of independence and brings real big-cap and digital experience, which Newton — who has never run a public company before — would otherwise lack. The addition of Bill Michael at the end of January 2026 deepens the professional-services and Big-4 bench, which is genuinely useful for a consultancy preparing M&A integration and accounting judgements (goodwill: ~$233m at year-end is the single largest balance-sheet item).
The structural weakness is scale and tenure: 6 directors at year-end (now 7), with 5 of them appointed at or around the 2020 AIM IPO. They have served together long enough to be cohesive, but no NED rotation has happened in five years and the Stranner/Retter pair are simultaneously committee-chairs and audit-committee/remuneration-committee members. The Code's "must consider tenure" pressure builds from year seven; that clock is ticking from mid-2027.
Auditor: Crowe U.K. LLP, in its 7th uninterrupted year (since FY2019). Materiality ~$2.0m (5% of pre-tax profit). Key audit matters in FY25 were acquisition accounting (TRC), goodwill impairment (~$233m carrying value), and revenue recognition. No qualifications, no emphasis-of-matter, no going-concern issues. Audit rotation will need to be considered ahead of the 10-year limit.
5. The Verdict
Governance Grade
Economic Alignment / 10
Board Quality / 10
Pay Discipline / 10
Strongest positives. A founder who still owns 22.85% of the company (~$113m) writes a powerful incentive contract that no policy document can replicate. The Chairman is genuinely heavyweight, the audit and rem committees are CA-qualified independents, the auditor is clean, the balance sheet is conservative, and the dividend record is consistent with disciplined cash generation. There is no related-party self-dealing, no promoter pledging, no controversial director loans, no auditor disagreements.
Real concerns. Three explicit UKCG opt-outs (no clawback, sub-five-year RSA vesting, no shareholding policy); performance targets undisclosed; the founder is a quiet net seller and shows no track record of open-market buying; March 2026 employee option repricing transferred ~$13–19m of theoretical value from shareholders to staff (excluding directors); thin succession bench under the founder/co-founder pair; and one new NED carries reputational baggage from his KPMG exit.
The one thing that would move the grade.
- Upgrade to A− if the FY26 annual report introduces malus/clawback, formal director shareholding requirements (e.g., 200% salary), and discloses retrospective bonus targets. Plus a clean year of director open-market buying (not just selling) at current prices.
- Downgrade to B− if Newton continues to sell into strength while the company keeps repricing or re-issuing employee options, or if the goodwill on the balance sheet (~$233m, ~78% of total assets) takes a material impairment in FY26 alongside an earnings miss.